EUVIMEDEUVIMED entdecken
Open Access

Pharmacological modulators of epithelial immunity uncovered by synthetic genetic tracing of SARS-CoV-2 infection responses

Ben Jiang iD, Matthias Jürgen Schmitt iD, Ulfert Rand iD, Carlos Company iD, Yuliia Dramaretska iD, Melanie Grossmann, Michela Serresi iD, Luka Čičin-Šain iD, Gaetano Gargiulo iD

Science Advances · 2023

DOI: 10.1126/sciadv.adf4975 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2023. Verfasst von Ben Jiang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Max-Delbrück-Center for Molecular Medicine (MDC), Robert-Rössle-Str. 10, 13092 Berlin, Germany. Hauptthemen laut MEDLINE: COVID-19, Interferon Type I. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epithelial immune responses govern tissue homeostasis and offer drug targets against maladaptation. Here, we report a framework to generate drug discovery–ready reporters of cellular responses to viral infection. We reverse-engineered epithelial cell responses to SARS-CoV-2, the viral agent fueling the ongoing COVID-19 pandemic, and designed synthetic transcriptional reporters whose molecular logic comprises interferon-α/β/γ and NF-κB pathways. Such regulatory potential reflected single-cell data from experimental models to severe COVID-19 patient epithelial cells infected by SARS-CoV-2. SARS-CoV-2, type I interferons, and RIG-I drive reporter activation. Live-cell image–based phenotypic drug screens identified JAK inhibitors and DNA damage inducers as antagonistic modulators of epithelial cell response to interferons, RIG-I stimulation, and SARS-CoV-2. Synergistic or antagonistic modulation of the reporter by drugs underscored their mechanism of action and convergence on endogenous transcriptional programs. Our study describes a tool for dissecting antiviral responses to infection and sterile cues and rapidly discovering rational drug combinations for emerging viruses of concern.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Interferon Type IHumansSARS-CoV-2PandemicsEpithelial Cells

Substanzen

Interferon Type I

Autor:innen und Institutionen

  • Max-Delbrück-Center for Molecular Medicine (MDC), Robert-Rössle-Str. 10, 13092 Berlin, Germany.
  • Helmholtz-Zentrum für Infektionsforschung GmbH (HZI), Inhoffenstraße 7, 38124 Braunschweig, Germany.

ORCID-Profile: Ben Jiang, Matthias Jürgen Schmitt, Ulfert Rand, Carlos Company, Yuliia Dramaretska, Michela Serresi, Luka Čičin-Šain, Gaetano Gargiulo

Zitieren

APA

Jiang, B., Schmitt, M. J., Rand, U., Company, C., Dramaretska, Y., Grossmann, M., Serresi, M., Čičin-Šain, L., & Gargiulo, G. (2023). Pharmacological modulators of epithelial immunity uncovered by synthetic genetic tracing of SARS-CoV-2 infection responses. Science Advances. https://doi.org/10.1126/sciadv.adf4975

Vancouver

Jiang B, Schmitt MJ, Rand U, Company C, Dramaretska Y, Grossmann M, et al. Pharmacological modulators of epithelial immunity uncovered by synthetic genetic tracing of SARS-CoV-2 infection responses. Science Advances. 2023. doi:10.1126/sciadv.adf4975

BibTeX
@article{Jiang2023,
  author = {Jiang, Ben and Schmitt, Matthias Jürgen and Rand, Ulfert and Company, Carlos and Dramaretska, Yuliia and Grossmann, Melanie and Serresi, Michela and Čičin-Šain, Luka and Gargiulo, Gaetano},
  title = {Pharmacological modulators of epithelial immunity uncovered by synthetic genetic tracing of SARS-CoV-2 infection responses},
  journal = {Science Advances},
  year = {2023},
  doi = {10.1126/sciadv.adf4975}
}
Kostenlos starten →